SCHEMBL4472769

SCHEMBL4472769

Cc1[nH]c(C)c(-c2ccc(-c3cc(C(F)(F)F)ccc3Cl)nc2)c(=O)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.45
SLC2A1 P11166 1/20 0.43
PTGES O14684 2/20 0.36
BIRC5 O15392 2/20 0.36
SMO Q99835 1/20 0.36
NPBWR1 P48145 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
IL2 P60568 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
JAK2 O60674 1/20 0.35
LMNA P02545 1/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
ARF6 P62330 1/20 0.34
EIF4E P06730 1/20 0.33
KIF20B Q96Q89 1/20 0.33
CDK4 P11802 1/20 0.33
CCND1 P24385 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4491220 0.92 SLC2A1 (0.43) KDM1ASLC2A1SMONPBWR1ALOX5AP
SCHEMBL4486314 0.91 SLC2A1 (0.43) KDM1ASLC2A1PTGESALOX5APFEN1
SCHEMBL4485644 0.88 FEN1 (0.44) SLC2A1ALOX5APFEN1
SCHEMBL4565033 0.87 SLC2A1 (0.43) KDM1ASLC2A1
SCHEMBL4492018 0.84 SLC2A1 (0.51) KDM1ASLC2A1MEN1KMT2A
SCHEMBL4473576 0.81 LMNA (0.40) SLC2A1KMT2ALMNA
SCHEMBL4564903 0.81 SLC2A1 (0.39) SLC2A1ALOX5APFEN1
SCHEMBL4492260 0.78 SLC2A1 (0.41) SLC2A1LMNA
SCHEMBL13049075 0.77 FEN1 (0.40) ALOX5APFEN1
SCHEMBL4490980 0.77 SCD (0.45) SLC2A1ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP KDM1A 1359/4885SLC2A1 2278/4885PTGES 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.